Novel CCNK molecular glue degradation agent, preparation method thereof and application of novel CCNK molecular glue degradation agent as medicine

Through the development of the new biphenyl CCNK molecular gel, the problem of CCNK overexpression in cancer has been solved, effective degradation of CCNK, reduced side effects of chemotherapy, significantly inhibited tumor cell growth, and improved the safety and effectiveness of chemotherapy.

CN118955493APending Publication Date: 2024-11-15GUANGDONG PHARMA UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411240042.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively degrade cyclin K (CCNK), which is overexpressed in a variety of cancers, and chemotherapy has strong lethality to rapidly dividing cells, resulting in serious side effects of chemotherapy, lack of effective degrading agents to prevent or treat cancer and Improve toxic and side effects of chemotherapy.

Method used

A new biphenyl CCNK molecular gel was developed to react with CCNK through specific compound structures to achieve its degradation, which is used to prevent or treat cancer, inflammation and improve chemotherapy toxic side effects.

Benefits of technology

This biphenyl CCNK molecular gel can effectively degrade CCNK protein, significantly inhibit tumor cell growth, reduce the damage of chemotherapy to immune cells and bone marrow, and improve the safety and effectiveness of chemotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955493A_ABST
    Figure CN118955493A_ABST
Patent Text Reader

Abstract

The invention relates to a degradation agent containing an effective amount of novel CCNK molecular glue as shown in a general formula (I), a preparation method of the degradation agent and application of a pharmaceutical composition containing the derivative in preparation of drugs for treating CCNK related diseases, and compared with the prior art, the degradation agent has a wider application prospect. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicinal chemistry and relates to a new type of biphenyl molecular glue, which is used for triggering polyubiquitination and degradation of CCNK (cell cycle protein K). The derivative structure of the invention is unique and novel in this field. Background Art

[0002] The control of the cell cycle is usually maintained by three different types of proteins, called CDK (cyclin-dependent kinase), cyclin and CKI (CDK inhibitor). Cyclin is a class of proteins whose expression levels change periodically during the cell cycle regulation process. Cyclin was first discovered by Tom Evans in 1983 when he was studying the cell cycle of sea urchins. It is a family of proteins that mainly controls the cell cycle process by activating CDK activity and other cell cycle-related enzymes. In vertebrates, cyclins include types A, B, D, E, F, G, H and K. Cyclin-dependent kinases (CDK) can be divided into two categories: cell cycle-related CDK (CDK1, CDK2, CDK4 and CDK6) and transcription-related CDK (CDK7, CDK8, CDK9, CDK12 and CDK13). Among them, cyclin K (Cyclin K or CCNK), which is most similar to cyclins C and H, is considered to be a new member of the transcriptional cyclin family. Initially, CCNK was proposed to play a dual role in controlling the activity of CDK and RNA polymerase II (RNAP II). Existing studies have shown that CCNK forms a functional complex with CDK9, CDK12, and CDK13, indicating that this protein is involved in the regulation of gene transcription and DNA damage response, as well as maintaining embryonic stem cell pluripotency and genomic stability.

[0003] It has been reported that CCNK mRNA expression is increased in many types of cancer, including cholangiocarcinoma, esophageal cancer, glioblastoma, low-grade glioma, pancreatic cancer, gastric adenocarcinoma, and thymoma. In addition, the overexpression of CCNK in disease has been verified in cancer cell lines and cancer patient samples in the scientific literature: CCNK is overexpressed in various human cancer cell lines and invasive breast ductal carcinoma samples. Compared with early breast cancer, elevated CCNK levels were also found in advanced breast cancer. CCNK expression was significantly enhanced in patients with primary prostate cancer, and increased CCNK expression was associated with decreased biochemical recurrence-free survival. CCNK can be used as an independent biomarker to predict biochemical recurrence-free survival in patients with prostate cancer. Increased CCNK levels in lung cancer were observed from lung adenocarcinoma tissue arrays, and the study also found that increased CCNK expression was associated with more advanced disease stages. Therefore, the compounds in this study are expected to play an important role in the treatment of various cancers as CCNK degraders, and their research and drug development have broad prospects.

[0004] In addition, in addition to tumor cells, some normal cells in the human body are also in a state of rapid division, such as blood cells and immune cells. Because chemotherapy has a strong lethality to these rapidly dividing cells, a major side effect of chemotherapy is the killing of bone marrow and immune cells, which is also the main limiting factor of chemotherapy doses. CCNK is also necessary for growth and proliferation in hematopoietic stem cells and progenitor cells (HSPCs), which are "reservoirs" formed by all blood and immune system cells. Therefore, CCNK degraders are used before chemotherapy to suspend the cell cycle of immune cells and HSPCs, reduce their damage and death, and then enhance immune response and reduce chemotherapy-induced bone marrow suppression, thereby treating non-CCNK-dependent tumors and improving the prognosis of chemotherapy patients. Therefore, the present invention may also have a great potential for changing chemotherapy regimens. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide for the first time a new biphenyl CCNK molecular glue and a preparation method thereof, thereby providing the possibility for applying CCNK molecular glue in preventing and / or treating cancer, inflammation, improving the toxic side effects of chemotherapy, etc.

[0006] The novel biphenyl CCNK molecular glue of the present invention contains an effective amount of a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof:

[0007]

[0008] in,

[0009] R is selected from hydrogen, alkyl, cycloalkyl, aryl, wherein the alkyl, cycloalkyl, aryl is optionally further substituted by one or more groups selected from hydrogen, halogen, alkyl, alkoxy, cycloalkyl;

[0010] R1 and R2 are each independently selected from hydrogen, alkyl, or R1 and R2 are linked to form a carbocyclic ring;

[0011] R3 is selected from hydrogen, halogen, alkyl, trifluoromethyl;

[0012] R4 is selected from any of the following structures:

[0013] Wherein, R5 is optionally selected from hydrogen, alkyl, cycloalkyl, trifluoromethyl, R6 is optionally selected from alkyl, cycloalkyl, aryl, five-membered to six-membered aromatic heterocyclic group, W, X, Y and Z are each independently selected from N, CR7, and the R7 is optionally selected from hydrogen, halogen, alkyl, cycloalkyl, carboxyl, cyano, trifluoromethyl.

[0014] The preferred compounds of the present invention are represented by general formula (I) or pharmaceutically acceptable salts thereof:

[0015] in,

[0016] R is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, wherein the alkyl, cycloalkyl, aryl are optionally further substituted by one or more groups selected from hydrogen, halogen, alkyl, alkoxy, cycloalkyl;

[0017] R1 and R2 are each independently selected from hydrogen, C1-C6 alkyl, or R1 and R2 are linked to form a carbocyclic ring;

[0018] R3 is selected from hydrogen, halogen, C1-C6 alkyl, trifluoromethyl;

[0019] R4 is selected from any of the following structures:

[0020] Wherein, R5 is optionally selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, trifluoromethyl, R6 is optionally selected from alkyl, cycloalkyl, aryl, five-membered to six-membered aromatic heterocyclic group, W, X, Y and Z are each independently selected from N, CR7, and the R7 is optionally selected from hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, carboxyl, cyano, trifluoromethyl.

[0021] More preferred compounds of the present invention include, but are not limited to;

[0022] 2-(4-(Furan-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (1)

[0023] 2-(4-(Furan-2-yl)-3-methylphenyl)-N-(5-methylthiazol-2-yl)acetamide (2)

[0024] 2-(4-(Furan-3-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (3)

[0025] 5-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)furan-2-carboxylic acid (4)

[0026] 2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (5)

[0027] 2-(4-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (6)

[0028] 2-(4-(1-methyl-1H-pyrazol-5-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (7)

[0029] N-(5-Methylthiazol-2-yl)-2-(4-(thiophen-2-yl)phenyl)acetamide (8)

[0030] 2-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (9)

[0031] N-(5-Methylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide (10)

[0032] N-(5-Methylthiazol-2-yl)-2-(4-(pyridin-3-yl)phenyl)acetamide (11)

[0033] 2-(4-(6-Methylpyridin-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (12)

[0034] 2-(4-(5-methylpyridin-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (13)

[0035] 2-(4-(4-Methylpyridin-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (14)

[0036] 2-(4-(3-methylpyridin-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (15)

[0037] 2-(4-(4-cyanopyridin-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (16)

[0038] N-(5-Methylthiazol-2-yl)-2-(4-(pyrimidin-2-yl)phenyl)acetamide (17)

[0039] N-(5-Methylthiazol-2-yl)-2-(4-(pyrazin-2-yl)phenyl)acetamide (18)

[0040] N-(5-Methylthiazol-2-yl)-2-(4-(pyridazin-3-yl)phenyl)acetamide (19)

[0041] N-(5-phenylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide (20)

[0042] 2-(4-(Pyridin-2-yl)phenyl)-N-(thiazol-2-yl)acetamide (21)

[0043] N-(5-isopropylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide (22)

[0044] N-(5-Methylthiazol-2-yl)-2-(4-(oxazol-2-yl)phenyl)acetamide (24)

[0045] 2-(4-(Oxazol-2-yl)phenyl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide (25)

[0046] N-(5-isopropylthiazol-2-yl)-2-(4-(oxazol-2-yl)phenyl)acetamide (26)

[0047] 1-(4-(Furan-2-yl)phenyl)-N-(5-methylthiazol-2-yl)cyclopropane-1-carboxamide (27)

[0048] 5-Methyl-N-(4-(pyridin-2-yl)benzyl)thiazole-2-carboxamide (29)

[0049] 2-(4-Acetylaminophenyl)-N-(5-methylthiazol-2-yl)acetamide (31)

[0050] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)-1H-pyrazole-3-carboxamide (32)

[0051] N-(4-(2-(5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)-1H-imidazole-2-carboxamide (33)

[0052] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)picolinamide (34)

[0053] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)benzamide (35)

[0054] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)isoxazole-5-carboxamide (36)

[0055] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)oxazole-5-carboxamide (37)

[0056] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)oxazole-2-carboxamide (38)

[0057] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)isoxazole-3-carboxamide (39)

[0058] Another aspect of the present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of the compound or a pharmaceutically acceptable salt thereof and a suitable carrier, diluent or excipient.

[0059] The invention relates to use of the compound or its pharmaceutically acceptable salt and pharmaceutical composition in preparing medicines for treating CCNK-mediated diseases.

[0060] The present invention also relates to the use of the compound or its pharmaceutically acceptable salt and pharmaceutical composition in preparing drugs for preventing and / or treating cancer, inflammation and toxic side effects of chemotherapy.

[0061] Detailed description of the invention

[0062] Unless otherwise stated, the following terms used in the specification and claims have the following meanings.

[0063] Any general formula or structure shown herein, including compounds of general formula (I), is also intended to represent unlabeled and isotopically labeled forms of the compounds. Isotope-labeled compounds have the structure shown in the molecular formula given herein, except that one or more atoms are replaced by atoms with a selected atomic mass or mass number. Examples of isotopes that may be included in the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, and in the compounds of the present invention, any atom that is not explicitly indicated as a specific isotope is intended to represent any stable isotope of the atom. Unless otherwise stated, when a position is explicitly indicated with "H" or "hydrogen", it should be understood that the position is hydrogen of its isotopic composition. Therefore, in the compounds of the present invention, any atom explicitly indicated as deuterium (D) is intended to represent deuterium.

[0064] "Pharmaceutical composition" means a mixture containing one or more compounds of the present invention and other chemical components, such as pharmaceutically acceptable carriers and excipients. Pharmaceutical compositions can promote the absorption of active ingredients by organisms and facilitate the active ingredients to exert their biological activity in vivo.

[0065] "Cancer" refers to any malignant tumor in tissue and cell type. Examples of cancer may include cancers that may be caused by abnormal adhesion cells, or cancers that may be caused by abnormal blood cells (e.g., leukemia, lymphoma, multiple myeloma). Specifically, examples of cancers that may be caused by abnormal adhesion cells may include lung cancer (e.g., squamous cell carcinoma, non-small cell lung cancer such as adenocarcinoma, large cell carcinoma, and small cell carcinoma), gastrointestinal cancer (e.g., gastric cancer, colorectal cancer, small intestine cancer, rectal cancer), pancreatic cancer, kidney cancer, liver cancer, thymus cancer, spleen cancer, thyroid cancer, adrenal cancer, prostate cancer, bladder cancer, ovarian cancer, uterine cancer (e.g., endometrial cancer, cervical cancer), bone cancer, skin cancer, brain tumors, sarcomas, melanomas, germ cell tumors (e.g., neuroblastomas), adenocarcinomas, squamous cell carcinomas, solid cancers, epithelial cancers, and mesothelioma. In particular, the cancer may be a leukemia, in particular acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL), a chronic leukemia, such as chronic myeloid leukemia; adenoid cystic carcinoma, osteosarcoma, ovarian cancer, Ewing's tumor, lung adenocarcinoma and prostate cancer, lymphoma, neuroblastoma, gastrointestinal cancer, endometrial cancer, medulloblastoma, prostate cancer, esophageal cancer, breast cancer, thyroid cancer, meningioma, liver cancer, colorectal cancer, pancreatic cancer, chondrosarcoma, osteosarcoma, kidney cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0066] Figure 1 :Compound 24 degrades CCNK in cells (A) Degrades CCNK in A549 cells; (B) CCNK degrades DC 50 Graph.

[0067] Figure 2 :Compound 24 improves the histological characteristics of tumor-bearing mice: (A) Experimental process of tumor-bearing mouse model; (B) Photographing of tumor tissue; (C) Changes of tumor volume over time; (D) Tumor weight. One-way ANOVA and Tukey's multiple-comparison post hoc test were used for data statistical analysis (n=6), *P<0.05, **P<0.01, ***P<0.001 indicate significant differences compared with the model group.

[0068] Figure 3Effects of compound 24 on hepato-renal toxicity in tumor-bearing mice: (A) serum UA level; (B) serum ALP level, (C) serum BUN level; (D) serum CR level; (E) serum ALT level; (F) serum AST level; (G) serum TBIL level; (H) serum TBA level. One-way ANOVA and Tukey's multiple-comparison post hoc test were used for statistical analysis (n=6), *P<0.05, **P<0.01, ***P<0.001 indicate significant differences compared with the model group. DETAILED DESCRIPTION

[0069] The present invention will be further described below in conjunction with the examples. It should be noted that the following examples are only for illustration, and are not intended to limit the present invention. Various changes made by those skilled in the art based on the teachings of the present invention should be within the scope of protection of the claims of this application.

[0070] The synthetic preparation route of the compound of the present invention:

[0071] Synthetic route 1:

[0072]

[0073] Reagents and conditions: (a) methanol, concentrated sulfuric acid, 70°C, 3 hours; (b) sodium carbonate, tetrakis(triphenylphosphine)palladium, 1,4-dioxane / water, under N2 protection, 80°C, 16 hours; (c) lithium hydroxide monohydrate, tetrahydrofuran / methanol / water, room temperature, overnight; (d) HBTU, N,N-diisopropylethylamine, dichloromethane, room temperature, 6 hours.

[0074] After dissolving p-bromophenylacetic acid (1.0 equiv) in methanol, concentrated sulfuric acid was added dropwise with stirring, and then refluxed at 70°C for 3 hours. After the reaction was completed, it was cooled to room temperature, quenched with water, extracted with ethyl acetate, and the organic phases were combined and purified by column chromatography to obtain 2b. Subsequently, 2b (1.2 equiv) was dissolved in a mixed solvent (15 mL) of 1,4-dioxane / water (9:1, v / v), and furan-2-boronic acid pinacol ester (1.0 equiv), sodium carbonate (3.0 equiv), and tetrakis(triphenylphosphine)palladium (0.05 equiv) were added in sequence. Under the protection of N2, the mixture was heated to 80°C in an oil bath and refluxed for 18 hours. After the reaction is complete, cool to room temperature, filter under reduced pressure, spin-dry the filtrate, and purify by column chromatography to obtain 4a. 4a (1 equiv) was dissolved in a mixed solvent (14 mL) of tetrahydrofuran / methanol / water (3:3:1), and lithium hydroxide monohydrate (1.5 equiv) was added. The reaction was allowed to react at room temperature overnight. Dilute hydrochloric acid was added dropwise to adjust the pH to 3-4 to precipitate a white solid, which was filtered and dried to obtain 5a. 5a (1.0 equiv) was dissolved in dichloromethane, and then HBTU (1.1 equiv), N,N-diisopropylethylamine (3 equiv) and 6a (1.1 equiv) were added in sequence. The reaction was allowed to react at room temperature for 6 hours, spin-dried, water was added, and the mixture was extracted three times with ethyl acetate. The organic phases were combined and purified by column chromatography to obtain the target compound.

[0075] Synthetic route 2:

[0076]

[0077] Reagents and conditions: (a) sodium carbonate, tetrakis(triphenylphosphine)palladium, 1,4-dioxane / water, under N2 protection, 80°C, 16 hours; (b) lithium hydroxide monohydrate, tetrahydrofuran / methanol / water, room temperature; (c) HBTU, N,N-diisopropylethylamine, dichloromethane, room temperature, 6 hours.

[0078] Commercially available 4-boronic acid pinacol ester phenylacetic acid methyl ester (1 equiv) was used as the starting material and fully dissolved in a mixed solvent (15 mL) of 1,4-dioxane / water (9:1, v / v). 2-bromothiophene (1.2 equiv), sodium carbonate (3.0 equiv), and tetrakis(triphenylphosphine)palladium (0.05 equiv) were added in sequence. Under N2 protection, the mixture was heated to 80°C in an oil bath and refluxed for 18 h. After the reaction is complete, cool to room temperature, extract, combine the organic phases, and purify by column chromatography to obtain 9a, which is dissolved in a mixed solvent (14 mL) of tetrahydrofuran / methanol / water (3:3:1), and lithium hydroxide monohydrate (1.5 equiv) is added. The reaction is allowed to react at room temperature overnight, the solvent is dried by spin drying, and dilute hydrochloric acid is added dropwise to adjust the pH to 3-4 to precipitate a white solid, which is filtered and dried to obtain 10a. 10a (1.0 equiv) is dissolved in dichloromethane, and then HBTU (1.1 equiv), N,N-diisopropylethylamine (3 equiv) and 11b (1.1 equiv) are added in sequence, and the reaction is allowed to react at room temperature for 6 hours, and the reaction is dried by spin drying. The organic phases are combined and purified by column chromatography to obtain the target compound.

[0079] Synthetic route 3:

[0080]

[0081] Reagents and conditions: (a) sodium carbonate, tetrakis(triphenylphosphine)palladium, 1,4-dioxane / water, under N2 protection, 80°C, 16 hours; (b) trifluoroacetic acid, dichloromethane, reaction in an ice bath for 4 hours; (c) HBTU, N,N-diisopropylethylamine, dichloromethane, room temperature, 6 hours.

[0082] 3-Amino-5-bromobenzoic acid methyl ester (1 equiv) and 2-bromopyridine (1.2 equiv) were dissolved in sodium carbonate (3.0 equiv) and tetrakis(triphenylphosphine)palladium (0.05 equiv), and heated to 80°C in an oil bath under N2 protection and refluxed for 18 h. After the reaction was complete, the mixture was cooled to room temperature, filtered under reduced pressure, the filtrate was spin-dried, extracted, and the organic phases were combined and purified by column chromatography to obtain 13a. 13a (1 equiv) was dissolved in dichloromethane, and trifluoroacetic acid (5 equiv) was slowly added dropwise under ice bath, and the reaction was continued for 4 h. After the reaction is complete, the solvent is dried by spin-drying, 10 ml of dichloromethane is added, and the reaction is dried by spin-drying. The reaction is repeated three times. Saturated sodium bicarbonate solution is added dropwise with stirring, and the pH is adjusted to 9-10. A white solid is precipitated, and 14a is obtained by filtration and drying. 14a (1.0 equiv) is dissolved in dichloromethane, and HBTU (1.1 equiv), N,N-diisopropylethylamine (3 equiv) and 15a (1.1 equiv) are added in sequence. The reaction is carried out at room temperature for 6 hours, and the reaction is dried by spin-drying. Water is added and the mixture is extracted with ethyl acetate three times. The organic phases are combined and purified by column chromatography to obtain the target compound.

[0083] Synthetic route 4:

[0084]

[0085] Reagents and conditions: (a) HBTU, N,N-diisopropylethylamine, dichloromethane, room temperature, 6 hours; (b) Pd, dichloromethane:methanol (1:1), H2, overnight reaction at room temperature; (c) HBTU, N,N-diisopropylethylamine, dichloromethane, room temperature, 6 hours.

[0086] 16a (1.0 equiv) was dissolved in dichloromethane, and then HBTU (1.1 equiv), N, N-diisopropylethylamine (3 equiv) and 6a (1.1 equiv) were added in sequence, and the mixture was reacted at room temperature for 6 hours, and then dried by rotation. Water was added and extracted with ethyl acetate three times, and the organic phases were combined and purified by column chromatography to obtain 17a; 17a (1 equiv) was dissolved in a mixed system of dichloromethane and methanol, and a catalytic amount of Pd was added, and the mixture was reacted at room temperature overnight under a hydrogen atmosphere. After the reaction was complete, the mixture was filtered and dried by rotation to obtain 18a; 18a (1.0 equiv) was dissolved in dichloromethane, and then HBTU (1.1 equiv), N, N-diisopropylethylamine (3 equiv) and 19a (1.1 equiv) were added in sequence, and the mixture was reacted at room temperature for 6 hours, and then dried by rotation. Water was added and extracted with ethyl acetate three times, and the organic phases were combined and purified by column chromatography to obtain the target compound.

[0087] Example 1

[0088] 2-(4-(Furan-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (1)

[0089] After dissolving p-bromophenylacetic acid (1.0 equiv) in methanol, concentrated sulfuric acid (3%) was added dropwise with stirring, and the mixture was refluxed at 70°C for 3 hours. After the reaction was completed, the mixture was cooled to room temperature, water was added to quench the reaction, the solvent was dried, extracted with ethyl acetate, and the organic phases were combined and purified by column chromatography to obtain 2b. Subsequently, 2b (1.2 equiv) was dissolved in a mixed solvent (15 mL) of 1,4-dioxane / water (9:1, v / v), and furan-2-boronic acid pinacol ester (1.0 equiv), sodium carbonate (3.0 equiv), and tetrakis(triphenylphosphine)palladium (0.05 equiv) were added in sequence. The mixture was heated to 80°C in an oil bath and refluxed for 18 hours under N2 protection. After the reaction is complete, cool to room temperature, filter under reduced pressure, spin dry the filtrate, extract, combine the organic phases and purify by column chromatography to obtain 4a. Dissolve 4a (1 equiv) in a mixed solvent (14 mL) of tetrahydrofuran / methanol / water (3:3:1), add lithium hydroxide monohydrate (1.5 equiv), react at room temperature overnight, spin dry the solvent, add dilute hydrochloric acid dropwise, adjust the pH to 3-4 to precipitate a white solid, filter and dry to obtain 5a. Dissolve 5a (1.0 equiv) in dichloromethane, then add HBTU (1.1 equiv), N, N-diisopropylethylamine (3 equiv) and 6a (1.1 equiv) in sequence, react at room temperature for 6 hours, spin dry, add water and extract three times with ethyl acetate, combine the organic phases and purify by column chromatography to obtain the target compound. Yield: 60.3%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.16(s,1H),7.73(s,1H),7.66(d,J=8.0Hz,1H),7.52(d,J=8.2Hz,1H),7.36(d,J=8.0Hz,1H ),7.27(d,J=8.2Hz,1H),7.13(s,1H),6.91(d,J=3.4Hz,1H),6.60-6.56(m,1H),3.74(d,J=10.3Hz,2H),2.32(s,3H). 13 C NMR (101MHz, DMSO-d6) δ169.17,156.60,153.35,143.27,134.92,134.73,130.22,129.44,123.94,120.51,112.52,106.14,41.79,11.53.TOF-MS m / z:calcd for:C 16 H 15 N2O2S + [M+H] + :299.0849,found:299.0844.

[0090] Example 2

[0091] 2-(4-(Furan-2-yl)-3-methylphenyl)-N-(5-methylthiazol-2-yl)acetamide (2)

[0092] The synthesis method is the same as compound 1. Yield: 68.6%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.15(s,1H),7.79-7.74(m,1H),7.63-7.57(m,1H),7.25-7.20(m,2H),7.15-7 .10(m,1H),6.69(d,J=3.4Hz,1H),6.61(dd,J=3.4,1.8Hz,1H),3.72(s,2H),2.43(s,3H),2.31(s,4H). 13 C NMR(101MHz,DMSO-d6)δ168.72,156.17,152.39,142.49,134.78,134.32,133.9 3,132.08,128.82,128.29,126.25,111.80,108.90,41.26,21.54,11.10.TOF-MS m / z:calcd for:C 17 H 17 N2O2S + [M+H] + :313.1005,found:313.0996.

[0093] Example 3

[0094] (3) 2-(4-(Furan-3-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (3)

[0095] The synthesis method is the same as compound 1. Yield: 69.4%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.14(s,1H),8.15(s,1H),7.72(s,1H),7.56(d,J=7.7Hz ,2H),7.32(d,J=7.8Hz,2H),7.12(s,1H),6.93(s,1H),3.73(s,2H),2.31(s,3H). 13C NMR (101MHz, DMSO-d6) δ168.85,156.19,144.29,139.21,134.77,133.71,130.56,129.70,126.23,125.60,120.14,108.72,41.35,11.10.TOF-MS m / z:calcd for:C 16 H 15 N2O2S + [M+H] + :299.0849,found:299.0843.

[0096] Example 4

[0097] 5-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)furan-2-carboxylic acid (4)

[0098] The synthesis method is the same as compound 1. Yield: 72.7%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.18(s,1H),7.77(d,J=7.9Hz,2H),7.42(d,J=8.0Hz,2H), 7.31(d,J=3.6Hz,1H),7.13(s,1H),7.11(d,J=3.6Hz,1H),3.78(s,2H),2.32(s,3H). 13 C NMR(101MHz,DMSO-d6)δ168.55,159.30,156.22,156.14,144.06,135.98,13 4.78,130.01,127.80,126.28,124.49,119.94,107.79,41.39,11.10.TOF-MS m / z:calcd for:C 17 H 15 N2O4S + [M+H] + :343.0747,found:343.0734.

[0099] Example 5

[0100] 2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (5)

[0101] The synthesis method is the same as compound 1. Yield: 68.1%, white powder. 1H NMR (400MHz, DMSO-d6) δ12.13(s,1H),8.09(s,1H),7.82(s,1H),7.50(d,J=7.8Hz ,2H),7.29(d,J=7.8Hz,2H),7.12(s,1H),3.85(s,3H),3.71(s,2H),2.31(s,3H). 13 C NMR (101MHz, DMSO-d6) δ168.94,156.21,135.98,134.77,132.66,131.24,129.69,127.71,126.22,124.99,121.67,41.33,38.67,11.10.TOF-MS m / z:calcd for:C 16 H 17 N4OS + [M+H] + :313.1118,found:313.1100.

[0102] Example 6

[0103] 2-(4-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (6)

[0104] The synthesis method is the same as compound 1. Yield: 63.3%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.13(s,1H),8.19(s,1H),7.82(s,1H),7.52(d,J=7.9Hz,2H),7.28(d,J=7.9H z,2H),7.12(s,1H),3.71(s,2H),2.54-2.47(m,1H),2.31(s,3H),1.10-1.04(m,2H),1.01-0.93(m,2H). 13 C NMR(101MHz,DMSO-d6)δ168.93,156.20,136.02,134.77,132.69,131.14,1 29.65,126.84,126.22,125.03,121.41,41.33,32.79,11.10,6.30.TOF-MS m / z:calcd for:C 18 H 19 N4OS + [M+H] + :339.1274,found:339.1262.

[0105] Example 7

[0106] 2-(4-(1-methyl-1H-pyrazol-5-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (7)

[0107] The synthesis method is the same as compound 1. Yield: 65.8%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.20(s,1H),7.53-7.39(m,5H),7.13(d,J=1.5Hz,1H),6.37(d,J=1.9Hz,1H),3.84(s,3H),3.80(s,2H),2.32(s,3H). 13 C NMR (101MHz, DMSO-d6) δ168.66,156.15,142.48,137.92,135.31,134.80,129.68,128.77,128.47,126.30,105.82,41.34,37.54,11.11.TOF-MS m / z:calcd for:C 16 H 17 N4OS + [M+H] + :313.1118,found:313.1102.

[0108] Example 8

[0109] N-(5-Methylthiazol-2-yl)-2-(4-(thiophen-2-yl)phenyl)acetamide (8)

[0110] The synthesis method is the same as compound 1. Commercially available 4-boronic acid pinacol ester phenylacetic acid methyl ester (1 equiv) was used as the starting material, which was fully dissolved in a mixed solvent (15 mL) of 1,4-dioxane / water (9:1, v / v), and 2-bromothiophene (1.2 equiv), sodium carbonate (3.0 equiv), and tetrakis(triphenylphosphine)palladium (0.05 equiv) were added in sequence. Under N2 protection, the mixture was heated to 80°C in an oil bath and refluxed for 18 h. After the reaction is complete, cool to room temperature, filter under reduced pressure, spin dry the filtrate, extract, combine the organic phases and purify by column chromatography to obtain 9a, which is dissolved in a mixed solvent (14 mL) of tetrahydrofuran / methanol / water (3:3:1), and lithium hydroxide monohydrate (1.5 equiv) is added. The reaction is carried out at room temperature overnight, the solvent is spin dried, dilute hydrochloric acid is added dropwise, the pH is adjusted to 3-4 to precipitate a white solid, and 10a is obtained by suction filtration and drying. 10a (1.0 equiv) is dissolved in dichloromethane, and then HBTU (1.1 equiv), N, N-diisopropylethylamine (3 equiv) and 11b (1.1 equiv) are added in sequence, and the reaction is carried out at room temperature for 6 hours, spin dried, water is added, and ethyl acetate is extracted three times. The organic phases are combined and purified by column chromatography to obtain the target compound. Yield: 66.7%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.16(s,1H),7.61(d,J=7.9Hz,2H),7.55-7.45(m,2H),7.35(d,J=7.8Hz,2H),7.18-7.08(m,2H),3.75(s,2H),2.32(s,3H). 13 C NMR (101MHz, DMSO-d6) δ168.72,156.17,143.15,134.79,134.48,132.41,130.00,128.52,126.26,125.58,125.50,123.61,41.28,11.11.TOF-MS m / z:calcd for:C 16 H 15 N2OS2 + [M+H] + :315.0620,found:315.0612.

[0111] Example 9

[0112] 2-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (9)

[0113] The synthesis method is the same as compound 8. Yield: 73.5%, white powder.1 H NMR (400MHz, DMSO-d6) δ12.21(s,1H),7.93(d,J=8.1Hz,2H),7.52(d,J=8.1Hz,2H),7.13(s,1H),3.85(s,2H),2.57(s,3H),2.32(s,3H). 13 C NMR(101MHz,DMSO-d6)δ 168.27,163.91,163.87,156.07,138.98,134.81,130.33,126.43,126.34,122.13,41.43,11.09,10.67.TOF-MS m / z:calcd for:C 15 H 15 N4O2S + [M+H] + :315.0910,found:315.0902.

[0114] Example 10

[0115] N-(5-Methylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide (10)

[0116] The synthesis method is the same as compound 8. Yield: 73.5%, white powder. 1 H NMR (400 MHz, DMSO-d δ )δ12.19(s,1H),8.68-8.63(m,1H),8.07-8.01(m,2H),7.96-7.91(m,1H),7.90-7.83(m,1 H),7.43(d,J=8.2Hz,2H),7.36-7.31(m,1H),7.15-7.11(m,1H),3.80(s,2H),2.32(s,3H). 13 C NMR (101MHz, DMSO-d6) δ168.71, 156.17, 155.80, 149.54, 137.32, 137.25, 13 6.04,134.78,129.66,126.59,126.26,122.56,120.14,41.39,11.10.TOF-MS m / z:calcd for:C 17 H 16 N3OS + [M+H] + :310.1009,found:310.1000.

[0117] Embodiment 11

[0118] N-(5-Methylthiazol-2-yl)-2-(4-(pyridin-3-yl)phenyl)acetamide (11)

[0119] The synthesis method is the same as compound 8. Yield: 77.8%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.19 (s, 1H), 8.88 (d, J = 2.4Hz, 1H), 8.59-8.51 (m, 1H), 8.07-8.0 2(m,1H),7.69(d,J=7.9Hz,2H),7.51-7.40(m,3H),7.13(s,1H),3.80(s,2H),2.32(s,3H). 13 CNMR(101MHz,DMSO-d6)δ168.74,156.17,148.31,147.47,135.59,135.41,13 5.20,134.79,134.22,130.05,126.99,126.28,123.98,41.30,11.11.TOF-MS m / z:calcd for:C 17 H 16 N3OS + [M+H] + :310.1009,found:310.1001.

[0120] Example 12

[0121] 2-(4-(6-Methylpyridin-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (12)

[0122] The synthesis method is the same as compound 8. Yield: 68.3%, white powder. 1 H NMR(400MHz,DMSO-d6)δ12.19(s,1H),8.04-7.99(m,2H),7.78-7.69(m,2H),7.45-7.40(m, 2H),7.19(dd,J=7.0,1.6Hz,1H),7.15-7.11(m,1H),3.79(s,2H),2.53(s,3H),2.32(s,3H). 13CNMR(101MHz,DMSO-d6)δ168.73,157.73,156.18,155.13,137.46,137.44,135.8 3,134.78,129.58,126.58,126.25,121.83,117.17,41.40,24.37,11.10.TOF-MS m / z:calcd for:C 18 H 18 N3OS + [M+H] + :324.1165,found:324.1155.

[0123] Embodiment 13

[0124] 2-(4-(5-methylpyridin-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (13)

[0125] The synthesis method is the same as compound 8. Yield: 71.6%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.18(s,1H),8.48(s,1H),8.01(d,J=8.1Hz,2H),7.82(d,J=8.1Hz ,1H),7.67(d,J=8.2Hz,1H),7.41(d,J=8.1Hz,2H),7.13(s,1H),3.79(s,2H),2.32(s,6H). 13 C NMR (101MHz, DMSO-d6) δ168.74,156.18,153.17,149.78, 137.54,137.32,135.6 3,134.77,131.76,129.60,126.30,126.25,119.55,41.39,17.64,11.09.TOF-MS m / z:calcdfor:C 18 H 18 N3OS + [M+H] + :324.1165,found:324.1153.

[0126] Embodiment 14

[0127] 2-(4-(4-Methylpyridin-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (14)

[0128] The synthesis method is the same as compound 8. Yield: 84.5%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.18(s,1H),8.49(d,J=4.9Hz,1H),8.03(d,J=8.1Hz,2H),7.78(s,1H), 7.42(d,J=8.1Hz,2H),7.17(d,J=4.9Hz,1H),7.13(s,1H),3.79(s,2H),2.38(s,3H),2.32(s,3H). 13 C NMR(101MHz,DMSO-d6)δ168.75,156.18,155.66,149.24,147.92,137.39,135.9 2,134.80,129.61,126.60,126.29,123.42,120.92,41.40,20.70,11.11.TOF-MS m / z:calcd for:C 18 H 18 N3OS + [M+H] + :324.1165,found:324.1157.

[0129] Embodiment 15

[0130] 2-(4-(3-methylpyridin-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (15)

[0131] The synthesis method is the same as compound 8. Yield: 77.6%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.21 (s, 1H), 8.50-8.44 (m, 1H), 7.73-7.67 (m, 1H), 7.51 (d, J = 8. 1Hz,2H),7.40(d,J=8.0Hz,2H),7.32-7.24(m,1H),7.14(d,1H),3.80(s,2H),2.32(s,6H). 13 CNMR(101MHz,DMSO-d6)δ169.22,157.89,156.62,147.29,139.35,139.10,135.2 4,135.17,130.94,129.53,129.29,126.68,122.74,41.84,20.25,11.56.TOF-MS m / z:calcd for:C 18 H 18 N3OS+ [M+H] + :324.1165,found:324.1152.

[0132] Example 16

[0133] 2-(4-(4-cyanopyridin-2-yl)phenyl)-N-(5-methylthiazol-2-yl)acetamide (16)

[0134] The synthesis method is the same as compound 8. Yield: 69.8%, white powder. 1 H NMR(400MHz,DMSO-d6)δ12.20(s,1H),8.90-8.87(m,1H),8.45(s,1H),8.14-8.09(m, 2H),7.81-7.76(m,1H),7.47(d,J=8.2Hz,2H),7.13(s,1H),3.82(s,2H),2.31(s,3H). 13 C NMR (101MHz, DMSO-d6) δ168.57,156.98,156.15,150.74,137.22,135.59,134.79 ,129.89,126.92,126.29,123.95,122.11,120.59,117.04,41.39,11.10.TOF-MS m / z:calcd for:C 18 H 15 N4OS + [M+H] + :335.0961,found:335.0953.

[0135] Embodiment 17

[0136] N-(5-methylthiazol-2-yl)-2-(4-(pyrimidin-2-yl)phenyl)acetamide (17)

[0137] The synthesis method is the same as compound 8. Yield: 73.1%, white powder. 1 H NMR(400MHz,DMSO-d6)δ12.20(s,1H),8.89(d,J=4.2Hz,2H),8.35(d,J=7.6Hz,2H), 7.47(d,J=7.6Hz,2H),7.43(t,J=4.2Hz,1H),7.13(s,1H),3.83(s,2H),2.32(s,3H). 13C NMR (101MHz, DMSO-d6) δ168.55,163.16,157.73,156.15,137.98,135.88,134.78,129.66,127.77,126.29,119.88,41.49,11.10.TOF-MS m / z:calcd for:C 16 H 15 N4OS + [M+H] + :311.0961,found:311.0943.

[0138] Embodiment 18

[0139] N-(5-Methylthiazol-2-yl)-2-(4-(pyrazin-2-yl)phenyl)acetamide (18)

[0140] The synthesis method is the same as compound 8. Yield: 75.6%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.04 (s, 1H), 9.24-9.13 (m, 1H), 8.72-8.64 (m, 1H), 8.60-8.55 (m ,1H),8.09(d,J=7.9Hz,2H),7.49(d,J=7.9Hz,2H),7.12(s,1H),3.83(s,2H),2.32(s,3H). 13 CNMR(101MHz,DMSO-d6)δ168.33,155.97,151.22,144.03,143.07,141.72,136.85,134.53,134.39,129.68,126.59,126.10,41.26,10.78.TOF-MS m / z:calcd for:C 16 H 15 N4OS + [M+H] + :311.0961,found:311.0947.

[0141] Embodiment 19

[0142] N-(5-Methylthiazol-2-yl)-2-(4-(pyridazin-3-yl)phenyl)acetamide (19)

[0143] The synthesis method is the same as compound 8. Yield: 69.4%, off-white powder. 1H NMR (400MHz, DMSO-d6) δ12.22-11.90(m,1H),9.23-9.14(m,1H),8.16(dd,J=8.7,1.6Hz,1H),8.10(d,J =7.9Hz,2H),7.74(dd,J=8.6,4.9Hz,1H),7.51(d,J=7.9Hz,2H),7.12(s,1H),3.85(s,2H),2.33(s,3H). 13 C NMR (101MHz, DMSO-d6) δ168.33,158.14,155.96,150.17,136.93,134.64,134.53,129.66,127.20,126.71,126.08,123.77,41.25,10.77.TOF-MS m / z:calcd for:C 16 H 15 N4OS + [M+H] + :311.0961,found:311.0945.

[0144] Embodiment 20

[0145] N-(5-phenylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide (20)

[0146] The synthesis method is the same as compound 8. Yield: 67.7%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.56 (s, 1H), 8.67 (dd, J = 4.9, 1.7Hz, 1H), 8.07-8.03 (m, 2H), 8.00-7.93 (m, 2H), 7.92-7. 88(m,2H),7.61(s,1H),7.48(d,J=8.1Hz,2H),7.43(t,2H),7.40-7.36(m,1H),7.32(t,J=7.4Hz,1H),3.87(s,2H). 13 C NMR(101MHz,DMSO-d6)δ169.36,157.92,155.57,149.18,148.91,137.81,136.97,136.10 ,134.30,129.79,128.81,127.87,126.74,125.71,122.76,120.49,108.18,41.49.TOF-MS m / z:calcd for:C 22 H 18N3OS + [M+H] + :372.1165,found:372.1154.

[0147] Embodiment 21

[0148] 2-(4-(Pyridin-2-yl)phenyl)-N-(thiazol-2-yl)acetamide (21)

[0149] The synthesis method is the same as compound 8. Yield: 70.1%, white powder. 1 H NMR(400MHz,DMSO-d6)δ12.40(s,1H),8.68-8.62(m,1H),8.09-8.00(m,2H),7.96-7.90(m,1H) ,7.90-7.82(m,1H),7.51-7.42(m,3H),7.37-7.30(m,1H),7.20(d,J=3.6Hz,1H),3.84(s,2H). 13 C NMR (101MHz, DMSO-d6) δ169.01,158.00,155.80,149.54,137.69,137.36,137.24,135.95,129.69,126.60,122.55,120.14,113.55,41.41.TOF-MS m / z:calcd for:C 16 H 14 N3OS + [M+H] + :296.0852,found:296.0845.

[0150] Embodiment 22

[0151] N-(5-isopropylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide (22)

[0152] The synthesis method is the same as compound 8. Yield: 58.5%, white powder. 1H NMR (400MHz, DMSO-d6) δ12.20(s,1H),8.68-8.61(m,1H),8.07-8.00(m,2H),7.93(d,J=8.1Hz,1H),7.89-7.80(m,1H), 7.43(d, J=8.3Hz,2H),7.37-7.29(m,1H),7.18-7.12(m,1H),3.80(s,2H),3.14-3.03(m,1H),1.24(s,3H),1.23(s,3H). 13 C NMR(101MHz,DMSO-d6)δ169.17,156.26,156.24,149.99,139.83,137.76,137.6 9,136.51,132.47,130.04,127.03,123.00,120.58,41.88,27.16,24.84.TOF-MS m / z:calcd for:C 19 H 20 N3OS + [M+H] + :338.1322,found:338.1309.

[0153] Embodiment 23

[0154] N-(1H-Benzimidazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide (23)

[0155] The synthesis method is the same as compound 8. Yield: 66.5%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.02(s,1H),11.86(s,1H),8.69-8.62(m,1H),8.10-8.03(m,2H),7.94(d,J=8.0Hz,1H),7.89-7. 82(m,1H),7.49(d,J=8.1Hz,2H),7.46-7.41(m,2H),7.33(dd,J=7.4,4.8Hz,1H),7.08(dd,J=5.9,3.2Hz,2H), 3.85(s,2H). 13 C NMR (101MHz, DMSO-d6) δ170.26,155.79,149.54,146.54,137.30,137.24,136.16,129.67,126.56,122.55,121.06,120.13,42.08.TOF-MS m / z:calcd for:C20 H 17 N4OS + [M+H] + :329.1397,found:329.1386.

[0156] Embodiment 24

[0157] N-(5-Methylthiazol-2-yl)-2-(4-(oxazol-2-yl)phenyl)acetamide (24)

[0158] The synthesis method is the same as compound 8. Yield: 37.9%, white powder. 1 H NMR(400MHz,DMSO-d6)δ12.20(s,1H),8.20(s,1H),7.95(d,J=8.2Hz,2H),7.4 7(d,J=8.2Hz,2H),7.37(s,1H),7.16-7.10(m,1H),3.82(s,2H),2.32(s,3H). 13 C NMR (101MHz, DMSO-d6) δ168.41,160.74,156.12,140.04,137.67,134.78,130.06,128.51,126.30,126.01,125.62,41.43,11.09.TOF-MS m / z:calcd for:C 15 H 14 N3O2S + [M+H] + :300.0801,found:300.0796.

[0159] Embodiment 25

[0160] 2-(4-(Oxazol-2-yl)phenyl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide (25)

[0161] The synthesis method is the same as compound 8. Yield: 59.2%, white powder. 1 H NMR (400MHz, DMSO-d6) δ13.01(s,1H),8.20(s,1H),8.11(s,1H),7.96(d,J=8.3Hz,2H),7.49(d,J=8.2Hz,2H),7.37(s,2H),3.93(s,2H). 13C NMR (101MHz, DMSO-d6) δ169.99,160.88,160.70,140.81,140.10,136.94,130.21,128.54,128.47,126.06,125.79,124.20,41.25.TOF-MS m / z:calcd for:C 15 H 11 N3F3O2S + [M+H] + :354.0519,found:354.0508.

[0162] Embodiment 26

[0163] N-(5-isopropylthiazol-2-yl)-2-(4-(oxazol-2-yl)phenyl)acetamide (26)

[0164] The synthesis method is the same as compound 8. Yield: 45.9%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.21(s,1H),8.19(s,1H),7.94(d,J=8.3Hz,2H),7.47(d,J=8.2Hz ,2H),7.36(s,1H),7.16(s,1H),3.81(s,2H),3.13-3.04(m,1H),1.24(s,3H),1.23(s,3H). 13 CNMR(101MHz,DMSO-d6)δ168.50,160.78,155.78,140.10,139.53,137.75,132.08,130.06,128.55,126.06,125.65,41.51,26.75,24.43.TOF-MS m / z:calcd for:C 17 H 18 N3O2S + [M+H] + :328.1114,found:328.1104.

[0165] Embodiment 27

[0166] 1-(4-(Furan-2-yl)phenyl)-N-(5-methylthiazol-2-yl)cyclopropane-1-carboxamide (27)

[0167] The synthesis method is the same as compound 8. Yield: 60.2%, white powder. 1H NMR (400MHz, DMSO-d6) δ11.09(s,1H),7.75(s,1H),7.67(d,J=8.1Hz,2H),7.41(d,J=8.1Hz,2H),7.09(d,J=1.6 Hz,1H),6.94(d,J=1.6Hz,1H),6.64-6.56(m,1H),2.31(d,J=1.5Hz,3H),1.63-1.45(m,2H),1.28-1.12(m,2H). 13 C NMR(101MHz,DMSO-d6)δ175.07,161.14,153.32,143.44,138.89,132.34,131.7 8,130.47,129.79,124.02,112.57,106.39,31.06,15.77,15.70,11.54.TOF-MS m / z:calcd for:C 18 H 17 N2O2S + [M+H] + :325.1005,found:325.0997.

[0168] Embodiment 28

[0169] 1-(3-(Furan-2-yl)phenyl)-N-(5-methylthiazol-2-yl)cyclopropane-1-carboxamide (28)

[0170] The synthesis method is the same as compound 8. Yield: 56.2%, white powder. 1 H NMR (400MHz, DMSO-d6) δ11.32(s,1H),7.76-7.69(m,1H),7.65-7.61(m,1H),7.49-7.46(m,1H),7.42-7.34(m,1H),7.33-7. 26(m,1H),7.12-7.05(m,1H),6.98(d,J=3.4Hz,1H),6.62-6.57(m,1H),2.31(s,3H),1.56-1.50(m,2H),1.24-1.19(m,2H). 13C NMR(101MHz,DMSO-d6)δ175.47,152.85,142.97,132.28,130.53,130.15,129.10,128.8 3,128.80,124.65,122.44,121.61,112.09,106.14,30.87,15.18,15.10,11.07.TOF-MS m / z:calcd for:C 18 H 17 N2O2S + [M+H] + :325.1005,found:325.0999.

[0171] Embodiment 29

[0172] 5-Methyl-N-(4-(pyridin-2-yl)benzyl)thiazole-2-carboxamide (29)

[0173] 3-Amino-5-bromobenzoic acid methyl ester (1 equiv) and 2-bromopyridine (1.2 equiv) were dissolved in sodium carbonate (3.0 equiv) and tetrakis(triphenylphosphine)palladium (0.05 equiv), and heated to 80°C in an oil bath under N2 protection and refluxed for 18 h. After the reaction was complete, the mixture was cooled to room temperature, filtered under reduced pressure, the filtrate was spin-dried, extracted, and the organic phases were combined and purified by column chromatography to obtain 13a. 13a (1 equiv) was dissolved in dichloromethane, and trifluoroacetic acid (5 equiv) was slowly added dropwise under ice bath, and the reaction was continued for 4 h. After the reaction is complete, the solvent is dried by spin drying, 10 mL of dichloromethane is added, and the reaction is repeated three times. Saturated sodium bicarbonate solution is added dropwise under stirring, and the pH is adjusted to 9-10. A white solid is precipitated, and 14a is obtained by filtration and drying. 14a (1.0 equiv) is dissolved in dichloromethane, and then HBTU (1.1 equiv), N,N-diisopropylethylamine (3 equiv) and 15a (1.1 equiv) are added in sequence. The reaction is carried out at room temperature for 6 hours, and the reaction is dried by spin drying. Water is added and the mixture is extracted with ethyl acetate three times. The organic phases are combined and purified by column chromatography to obtain the target compound. Yield: 50.2%, yellow powder. 1 H NMR (400MHz, DMSO-d6) δ9.36(t,J=6.4Hz,1H),8.65(d,J=3.9Hz,1H),8.04(d,J=8.3Hz,2H),7.92(d,J=8. 1Hz,1H),7.89-7.84(m,1H),7.72(s,1H),7.44(d,J=8.3Hz,2H),7.37-7.29(m,1H),4.51(d,J=6.4Hz,2H). 13C NMR(101MHz,DMSO-d6)δ161.74,159.42,155.85,149.52,141.98,140.13,13 9.96,137.41,137.21,127.76,126.52,122.50,120.12,42.24,11.88.TOF-MS m / z:calcd for:C 17 H 16 N3OS + [M+H] + :310.1009,found:310.1002.

[0174] Embodiment 30

[0175] 5-Isopropyl-N-(4-(pyridin-2-yl)benzyl)-1H-pyrazole-3-carboxamide (30)

[0176] The synthesis method is the same as compound 29. Yield: 55.2%, yellow powder. 1 H NMR (400MHz, DMSO-d6) δ12.96(s,1H),8.02(d,J=8.0Hz,2H),7.91(d,J=8.0Hz,1H),7.88-7.80(m,1H),7.40(d,J=8.0Hz,2 H),7.35-7.28(m,1H),7.10(d,J=8.1Hz,1H),6.42(s,1H),4.47(d,J=6.3Hz,2H),3.04-2.91(m,1H),1.22(d,J=6.7Hz,6H). 13 C NMR(101MHz,DMSO-d6)δ162.22,155.95,150.90,149.54,141.06,137.25,128.66,127.62,126.45,122.50,101.54,41.69,25.14,22.33.TOF-MS m / z:calcd for:C 19 H 21 N4OS + [M+H] + :321.1710,found:321.1693.

[0177] Embodiment 31

[0178] 2-(4-Acetylaminophenyl)-N-(5-methylthiazol-2-yl)acetamide (31)

[0179] 16a (1.0 equiv) was dissolved in dichloromethane, and then HBTU (1.1 equiv), N, N-diisopropylethylamine (3 equiv) and 6a (1.1 equiv) were added in sequence, and the mixture was reacted at room temperature for 6 hours, and then dried by rotation. Water was added and extracted with ethyl acetate three times, and the organic phases were combined and purified by column chromatography to obtain 17a; 17a (1 equiv) was dissolved in a mixed system of dichloromethane and methanol, and a catalytic amount of Pd was added. The mixture was reacted at room temperature overnight under a hydrogen atmosphere. After the reaction was complete, the mixture was filtered and dried by rotation to obtain 18a; 18a (1.0 equiv) was dissolved in dichloromethane, and then HBTU (1.1 equiv), N, N-diisopropylethylamine (3 equiv) and 19a (1.1 equiv) were added in sequence, and the mixture was reacted at room temperature for 6 hours, and then dried by rotation. Water was added and extracted with ethyl acetate three times, and the organic phases were combined and purified by column chromatography to obtain the target compound. Yield: 67%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.09(s,1H),9.90(s,1H),7.51(d,J=7.6Hz,2H),7.22(d,J=8.1Hz,2H),7.11(s,1H),3.66(s,2H),2.31(s,3H),2.02(s,3H). 13 C NMR (101MHz, DMSO-d6) δ169.00,168.24,156.20,138.08,134.75,129.55,129.45,126.18,119.06,41.06,23.97,11.09.TOF-MS m / z:calcd for:C 14 H 15 N3NaO2S + [M+H] + :312.0777,found:312.0772.

[0180] Embodiment 32

[0181] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)-1H-pyrazole-3-carboxamide (32)

[0182] The synthesis method is the same as compound 31. Yield: 62%, white powder. 1H NMR(400MHz,DMSO-d6)δ 13.41(s,1H),12.13(s,1H),10.02(s,1H),7.94-7.84(m,1H),7.75(d,J=8.1Hz,2H),7 .26(d,J=8.1Hz,2H),7.17-7.08(m,1H),6.84-6.72(m,1H),3.69(s,2H),2.32(s,3H). 13 C NMR (101MHz, DMSO-d6) δ169.00,160.42,156.22,146.72,134.75,130.40,129.35,126.17,120.29,105.66,41.11,11.10.TOF-MS m / z:calcd for:C 16 H 16 N5O2S + [M+H] + :342.1019,found:342.1008.

[0183] Embodiment 33

[0184] N-(4-(2-(5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)-1H-imidazole-2-carboxamide (33)

[0185] The synthesis method is the same as compound 31. Yield: 64%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.59(s,1H),10.34(s,1H),7.81-7.73(m,2H),7.31-7.21(m,4H),7.15-7.08(m,1H),3.69(s,2H),2.32(s,3H). 13 C NMR (101MHz, DMSO-d6) δ169.04,156.86,156.36,140.99,137.23,134.73,130.33,129.39,126.09,120.32,41.16,11.12.TOF-MS m / z:calcd for:C 16 H 16 N5O2S + [M+H] + :342.1019,found:342.1012.

[0186] Embodiment 34

[0187] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)picolinamide (34)

[0188] The synthesis method is the same as compound 31. Yield: 63%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.14(s,1H),10.62(s,1H),8.76-8.69(m,1H),8.19-8.11(m,1H),8.10-8.01(m,1H), 7.85(d,J=8.5Hz,2H),7.71-7.62(m,1H),7.30(d,J=8.5Hz,2H),7.15-7.08(m,1H),3.72(s,2H),2.32(s,3H). 13 C NMR(101MHz,DMSO-d6)δ168.94,162.40,156.20,149.89,148.44,138.16,137.09 ,134.75,130.58,129.47,126.93,126.17,122.38,120.35,41.12,11.10.TOF-MS m / z:calcd for:C 18 H 17 N4O2S + [M+H] + :353.1067,found:353.1058.

[0189] Embodiment 35

[0190] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)benzamide (35)

[0191] The synthesis method is the same as compound 31. Yield: 67%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.13 (s, 1H), 10.24 (s, 1H), 7.95 (d, J = 7.1Hz, 2H), 7.72 (d, J = 8.4 Hz,2H),7.61-7.48(m,4H),7.29(d,J=8.3Hz,2H),7.12(s,1H),3.71(s,2H),2.32(s,3H). 13C NMR(101MHz,DMSO-d6)δ169.00,165.51,156.23,137.93,134.94,134.76,13 1.59,130.31,129.41,128.42,127.67,126.21,120.47,41.13,11.11.TOF-MS m / z:calcd for:C 19 H 18 N3O2S + [M+H] + :352.1114,found:352.1109.

[0192] Embodiment 36

[0193] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)isoxazole-5-carboxamide (36)

[0194] The synthesis method is the same as compound 31. Yield: 59%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.14 (s, 1H), 10.75 (s, 1H), 8.81 (d, J = 2.0Hz, 1H), 7.70 (d, J = 8.5Hz ,2H),7.32(d,J=8.5Hz,2H),7.29-7.20(m,1H),7.16-7.06(m,1H),3.72(s,2H),2.32(s,3H). 13 C NMR (101MHz, DMSO-d6) δ168.85,162.62,156.18,154.01,151.90,136.49,134.77,131.36,129.61,126.21,120.81,106.80,41.09,11.10.TOF-MS m / z:calcd for:C 16 H 15 N4O3S + [M+H] + :343.0859,found:343.0852.

[0195] Embodiment 37

[0196] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)oxazole-5-carboxamide (37)

[0197] The synthesis method is the same as compound 31. Yield: 57%, white powder.1 H NMR(400MHz,DMSO-d6)δ12.14(s,1H),10.43(s,1H),8.65(s,1H),7.98(s,1H),7.67( d,J=8.5Hz,2H),7.30(d,J=8.5Hz,2H),7.18-7.07(m,1H),3.71(s,2H),2.32(s,3H). 13 C NMR(101MHz,DMSO-d6)δ 168.90,156.20,154.90,153.84,145.22,136.81,134.76,130.90,130.06,129.56,126.20,120.59,41.08,11.10.TOF-MS m / z:calcd for:C 16 H 15 N4O3S + [M+H] + :343.0859,found:343.0848.

[0198] Embodiment 38

[0199] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)oxazole-2-carboxamide (38)

[0200] The synthesis method is the same as compound 31. Yield: 53%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.14(s,1H),10.83(s,1H),8.40(s,1H),7.75(d,J=8.5Hz,2 H),7.54(s,1H),7.30(d,J=8.5Hz,2H),7.16-7.09(m,1H),3.71(s,2H),2.31(s,3H). 13 C NMR (101MHz, DMSO-d6) δ168.87,156.19,154.94,153.13,142.70,136.61,134.76,131.15,129.51,128.39,126.19,120.77,41.09,11.10.TOF-MS m / z:calcd for:C 16 H 15 N4O3S + [M+H] + :343.0859,found:343.0851.

[0201] Embodiment 39

[0202] N-(4-(2-((5-methylthiazol-2-yl)amino)-2-oxoethyl)phenyl)isoxazole-3-carboxamide (39)

[0203] The synthesis method is the same as compound 31. Yield: 58%, white powder. 1 H NMR (400MHz, DMSO-d6) δ12.14(s,1H),10.71(s,1H),9.17-9.13(m,1H),7.72(d,J=8.5Hz,2 H),7.30(d,J=8.5Hz,2H),7.15-7.09(m,1H),7.04-7.00(m,1H),3.71(s,2H),2.32(s,3H). 13 CNMR(101MHz,DMSO-d6)δ168.87,161.69,158.30,157.12,156.18,136.75,134.76,131.12,129.54,126.19,120.69,104.59,41.08,11.10.TOF-MS m / z:calcd for:C 16 H 15 N4O3S + [M+H] + :343.0859,found:343.0846.

[0204] Example 40 In vitro biological activity test

[0205] 1) 7000 A549 cells (or MDA-MB-231 cells, HepG2 cells) were cultured in a 96-well flat-bottom plate per well. After overnight culture, the culture medium in the well was removed, 100 μL of compounds of different concentrations prepared with complete culture medium were added, mixed, and cultured for 4 days; cell viability was measured using a cell counting kit-8 (CCK-8), 10 μL of CCK-8 was added to each well, mixed, incubated in an incubator for 1 hour, and the fluorescence intensity of the system was measured using a Thermo multi-function microplate reader. IC 50 GraphPadPrism was used for baseline correction, and the results are shown in Table 1. The results show that the compounds of the present invention have good broad-spectrum anti-tumor cell proliferation activity.

[0206] Table 1: Antiproliferative activity on tumor cells

[0207]

[0208]

[0209] Note: The inhibition rate is the average of three independent experiments, IC 50 Values ​​are means ± SD of three independent experiments.

[0210] 2) Western blot detection

[0211] Protein levels were determined by standard Western blotting. After A549 cells were cultured with different concentrations of compounds for 24 h, cells were harvested with trypsin and total protein was extracted with 1× RIPA lysis buffer (NCM Biotech, China). Then, equal amounts of protein (4-40 μg / lane) in the total cell lysate were separated by sodium dodecyl sulfate (8%, 10% or 12%) polyacrylamide gel electrophoresis, wet-transferred to PVDF membrane (Merck Millipore, Germany), blotted with CCNK primary antibody overnight, and then incubated with isotype-specific secondary antibody at 37°C for 1 h. The bound immune complexes were detected using the ChemiDOC XRS system (BioRad Laboratories, Hercules, CA). The experimental results are shown in the attached. Figure 1 The results showed that compound 24 could degrade CCNK protein in a dose-dependent manner, which degraded DC 50 It is 41.5nM, which is much better than the positive control HQ461.

[0212] Example 41 Pharmacokinetic Study

[0213] In order to prepare the preparation required for oral administration, compound 24 was dissolved in a mixture of 5% DMSO and 0.5% CMC-Na. After a single oral dose (3 mg / kg) in SD rats, blood samples were collected at predetermined time points, each sample volume was 200 μL. The blood samples were placed in a test tube containing sodium heparin and stored on ice. They were then centrifuged at 12,000g for 10 minutes at a temperature of 2 to 8 degrees Celsius and left for 1 hour after collection. For analysis, 50 μL aliquots of plasma samples should be precipitated with 200 μL of methanol, the mixture should be vortexed for 3 minutes, centrifuged at 12,000 rpm for 10 minutes, and the supernatant should be added with an internal standard for LC-MS / MS analysis. The results of the pharmacokinetic experiments are shown in Table 2. The results show that compound 24 has excellent in vivo pharmacokinetic properties and is suitable for oral administration.

[0214] Table 2: Pharmacokinetic parameters of compound 24

[0215]

[0216] Example 42 In vivo antitumor activity study

[0217] Six-week-old female Balb / c nude mice were purchased from Guangdong Medical Experimental Animal Center (License No.: SCXK(Y)2022-0002) and kept in an SPF barrier environment. During the entire experiment, the temperature and relative humidity of the animal room were controlled at 23±2°C and 50±10%, and the light / dark cycle was constant at 12 hours. Before starting the animal experiment, all mice were adaptively raised for one week. The mice were raised under specific pathogen-free conditions and had free access to feed and water. A549 cells in the logarithmic growth phase with a degree of confluence of 80% were collected, counted, and resuspended in PBS to 6×10 6 / 100μL density cell suspension, keep on ice for later use. Disinfect the right abdominal skin of the mouse with 75% ethanol, use a 1mL syringe to inject 100μL of cell suspension subcutaneously into the right abdomen of the mouse, slowly withdraw the needle, and gently press the mouse skin with a cotton swab for 30s to prevent extravasation of the cell suspension. Use a digital vernier caliper to measure the tumor size every other day. When the tumor volume grows to an average of about 100mm 3 After (tumor volume = (length × width 2) / 2), the mice were randomly divided into 4 groups, 6 in each group. Then, the model group was given 0.5% sodium carboxymethyl cellulose (CMC-Na), 24 low-dose groups (10 mg / kg), 24 medium-dose groups (20 mg / kg) and 24 high-dose groups (40 mg / kg) by gavage every day for 17 days. During the administration period, the weight and tumor volume of the mice were recorded every other day. Before sampling, the mice were fasted for 8 hours (free drinking water), and 2% sodium pentobarbital (50 mg / kg) was given for intraperitoneal anesthesia. Then, blood was collected by orbital bleeding. The mice were killed by cervical dislocation and fixed on the mouse platform. After the blood was collected, the complete tumor tissue was peeled off, weighed and photographed. The tumor tissue was placed in a 1.5 mL cryotube, quickly frozen in liquid nitrogen, taken out and stored at -80°C for later use. The total protein of the tumor tissue was subsequently extracted for Western blotting experiments to detect the expression of the target protein. The experimental results are attached. Figure 2 and Figure 3 The results showed that the tumor volume of mice in the low, medium and high dose groups of compound 24 was significantly smaller than that in the control group, and the tumor weight of mice was also significantly lower than that in the control group, indicating that compound 24 can inhibit the growth of transplanted tumors in vivo (Appendix Figure 2 In addition, compared with the model group, all doses of compound 24 had no significant effect on the levels of ALT, AST, ALP, TBA and TBIL in mouse serum, indicating that compound 24 had no obvious hepatotoxicity at pharmacological doses (Appendix Figure 3 ); In addition, CR, BUN and UA in the treatment group decreased significantly, indicating that compound 24 may have a better protective effect on renal function in the tumor-bearing state.

Claims

1. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof: in, R is selected from hydrogen, alkyl, cycloalkyl, aryl, wherein the alkyl, cycloalkyl, aryl are optionally further substituted by one or more groups selected from hydrogen, halogen, alkyl, alkoxy, cycloalkyl: R1 and R2 are each independently selected from hydrogen, alkyl, or R1 and R2 are linked to form a carbocyclic ring; R3 is selected from hydrogen, halogen, alkyl, trifluoromethyl; R4 is selected from any of the following structures: Wherein, R5 is selected from hydrogen, alkyl, cycloalkyl, trifluoromethyl, R6 is selected from alkyl, cycloalkyl, aryl, five-membered to six-membered aromatic heterocyclic group, W, X, Y and Z are each independently selected from N, CR7, and R7 is selected from hydrogen, halogen, alkyl, cycloalkyl, carboxyl, cyano, trifluoromethyl.

2. A compound of the general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof: in, R is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, wherein the alkyl, cycloalkyl, aryl are optionally further substituted with one or more groups selected from hydrogen, halogen, alkyl, alkoxy, cycloalkyl; R1 and R2 are each independently selected from hydrogen, C1-C6 alkyl, or R1 and R2 are linked to form a carbocyclic ring; R3 is selected from hydrogen, halogen, C1-C6 alkyl, trifluoromethyl; R4 is selected from any of the following structures: Wherein, R5 is optionally selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, trifluoromethyl, R6 is optionally selected from alkyl, cycloalkyl, aryl, five-membered to six-membered aromatic heterocyclic group, W, X, Y and Z are each independently selected from N, CR7, and the R7 is optionally selected from hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, carboxyl, cyano, trifluoromethyl.

3. The compound of general formula (I) as defined in any one of claims 1 to 2 is selected from:

4. A pharmaceutical composition comprising the compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof and a suitable carrier or excipient.

5. Use of a compound as defined in any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating CCNK-mediated diseases.

6. Use of the compound defined in any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 4, in the preparation of a medicament for preventing and / or treating cancer, inflammation, or ameliorating the toxic side effects of chemotherapy.

Citation Information

Cited By

  • Novel CCNK-targeting molecular gel degradation agent, preparation method therefor and use thereof

    WO2026051373A1